



SAFETY DATA SHEET

Revision date: 14-Apr-2015

Version: 3.0

Page 1 of 14

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Phenytoin Oral Suspension

Trade Name: Dilantin®, Dilantin-125®, Epanutin®, Epamin®, Epelin®

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for seizures and epilepsy.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2

EU Classification:

EU Indication of danger: Carcinogenic: Category 3
Toxic to Reproduction: Category 2

EU Risk Phrases:

R40 - Limited evidence of a carcinogenic effect
R61 - May cause harm to the unborn child.

Label Elements

Signal Word: Danger
Hazard Statements: H360D - May damage the unborn child
H351 - Suspected of causing cancer

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 2 of 14
Version: 3.0



Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	*
Ethyl alcohol (ethanol)	64-17-5	200-578-6	F; R11	Flam. Liq. 2 (H225)	< 1
Phenytoin	57-41-0	200-328-6	Carc.Cat.3;R40 Repr.Cat.2;R61 Xn;R22	Acute Tox 4 (H302) Carc. 2 (H351) Repr 1B (H360D)	0.5-2.5
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Concentrated orange oil	8008-57-9	Not Listed	Not Listed	Not Listed	*
Imitation banana oil	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	Not Listed	*
Carboxymethylcellulose sodium	9004-32-4	Not Listed	Not Listed	Not Listed	*
FD&C Yellow No. 6; (Sunset yellow)	2783-94-0	220-491-7	Not Listed	Not Listed	*
Magnesium aluminum silicate	1327-43-1	215-478-8	Not Listed	Not Listed	*
Polysorbate 40	9005-66-7	Not Listed	Not Listed	Not Listed	*
Purified water	7732-18-5	231-791-2	Not Listed	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	Not Listed	*
Vanillin	121-33-5	204-465-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

SUSPENSION

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 3 of 14
Version: 3.0

4. FIRST AID MEASURES

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure:	None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Use with adequate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 4 of 14
Version: 3.0

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Protect from freezing. Protect from light. Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Glycerin, USP

Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Czech Republic OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
Finland OEL - TWA	20 mg/m ³
France OEL - TWA	10 mg/m ³
Germany (DFG) - MAK	50 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	50 mg/m ³

Ethyl alcohol (ethanol)

ACGIH Threshold Limit Value (STEL)	1000 ppm
Australia TWA	1000 ppm 1880 mg/m ³
Austria OEL - MAKs	1000 ppm 1900 mg/m ³
Belgium OEL - TWA	1000 ppm 1907 mg/m ³
Bulgaria OEL - TWA	1000.0 mg/m ³
Czech Republic OEL - TWA	1000 mg/m ³
Denmark OEL - TWA	1000 ppm 1900 mg/m ³
Estonia OEL - TWA	500 ppm 1000 mg/m ³
Finland OEL - TWA	1000 ppm 1900 mg/m ³
France OEL - TWA	1000 ppm 1900 mg/m ³
Germany - TRGS 900 - TWAs	500 ppm 960 mg/m ³
Germany (DFG) - MAK	500 ppm 960 mg/m ³
Greece OEL - TWA	1000 ppm 1900 mg/m ³
Hungary OEL - TWA	1900 mg/m ³
Latvia OEL - TWA	1000 mg/m ³
Lithuania OEL - TWA	500 ppm 1000 mg/m ³
Netherlands OEL - TWA	260 mg/m ³

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 5 of 14
Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - TWAs:	1000 ppm
	1900 mg/m ³
Poland OEL - TWA	1900 mg/m ³
Portugal OEL - TWA	1000 ppm
Romania OEL - TWA	1000 ppm
	1900 mg/m ³
Russia OEL - TWA	1000 mg/m ³
Slovakia OEL - TWA	500 ppm
	960 mg/m ³
Slovenia OEL - TWA	1000 ppm
	1900 mg/m ³
Spain OEL - TWA	1000 ppm
	1910 mg/m ³
Sweden OEL - TWAs	500 ppm
	1000 mg/m ³
Switzerland OEL - TWAs	500 ppm
	960 mg/m ³
Vietnam OEL - TWAs	1000 mg/m ³

Phenytoin

Pfizer OEL TWA-8 Hr: 400 µg/m³

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical Method:

Analytical method available for Phenytoin. Contact Pfizer Inc for further information.

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 6 of 14
Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Suspension	Color:	Orange
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Sodium benzoate

No data available

Carboxymethylcellulose sodium

No data available

Polysorbate 40

No data available

Sucrose

No data available

Ethyl alcohol (ethanol)

No data available

Vanillin

No data available

FD&C Yellow No. 6; (Sunset yellow)

No data available

Purified water

No data available

Imitation banana oil

No data available

Concentrated orange oil

No data available

Citric acid, anhydrous

No data available

Glycerin, USP

No data available

Magnesium aluminum silicate

No data available

Phenytoin

Predicted 7.4 Log D 2.47

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

SUSPENSION

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 7 of 14
Version: 3.0

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	May cause eye irritation (based on components) .
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, gastrointestinal system and liver.
Known Clinical Effects:	The most common adverse effects observed with clinical use of phenytoin are lack of appetite, headache, dizziness, transient nervousness, ataxia, slurred speech, decreased coordination, mental confusion, insomnia, and GI disturbances (nausea, vomiting, and constipation). IV administration has been associated with hypotension and CNS depression. Mild hypersensitivity reactions (skin rashes) are common. Effects on blood- forming organs and the liver have occurred rarely. Other less common effects include swollen lymph nodes, sore mouth and symptoms of dependence/withdrawal. There is an unconfirmed association between the use of anticonvulsants during pregnancy and an increased risk of birth defects. This material has been shown to be secreted in low concentrations in human breast milk.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium benzoate

Rat	Oral	LD50	4,070 mg/kg
Mouse	Oral	LD50	1600mg/kg

Carboxymethylcellulose sodium

Mouse	Oral	LD50	> 27,000 mg/kg
Rat	Oral	LD50	27,000 mg/kg
Rabbit	Dermal	LD50	> 2000 mg/kg

Sucrose

Rat	Oral	LD50	29.7 g/kg
-----	------	------	-----------

Ethyl alcohol (ethanol)

Mouse	Oral	LD50	3450 mg/kg
Rat	Oral	LD50	7060mg/kg
Rat	Inhalation	LC50 10h	20,000ppm

Vanillin

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 8 of 14
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Rat Oral LD 50 1580 mg/kg

FD&C Yellow No. 6; (Sunset yellow)

Rat Oral LD50 > 10,000 mg/kg

Mouse Oral LD50 > 6,000mg/kg

Citric acid, anhydrous

Rat Oral LD50 3000 mg/kg

Glycerin, USP

Mouse Oral LD50 4090 mg/kg

Rat Oral LD50 12.6 g/kg

Rabbit Dermal LD50 > 10 g/kg

Rat Inhalation LC50 1hr > 570 mg/m³

Rat Dermal LD 50 > 21.9 g/kg

Phenytoin

Mouse Oral LD50 150 mg/kg

Rat Oral LD50 1635mg/kg

Rat Intravenous LD 50 96mg/kg

Rat IM LD 50 >337mg/kg

Rabbit Oral LD 50 >3000mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Ethyl alcohol (ethanol)

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Citric acid, anhydrous

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Glycerin, USP

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium benzoate

10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood

10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder

Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOAEL Liver, Kidney, Ureter, Bladder

Phenytoin

2 Week(s) Rat Oral <3125 ppm/day NOEL Bone marrow

2 Week(s) Mouse Oral <125 ppm/day NOEL Central Nervous System

13 Week(s) Rat Oral 300 ppm/day NOEL None identified

13 Week(s) Mouse Oral 150 ppm/day NOEL Blood forming organs, Gastrointestinal system, Liver

SUSPENSION

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 9 of 14
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sodium benzoate

Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity,

Phenytoin

Embryo / Fetal Development Mouse Oral 75 mg/kg/day NOEL Maternal toxicity, Fetotoxicity, Teratogenic
Embryo / Fetal Development Mouse Oral 45 mg/kg/day NOEL Teratogenic
Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOEL Fetotoxicity, Teratogenic
Embryo / Fetal Development Monkey Oral 10 mg/kg/day NOEL Fetotoxicity, Teratogenic
Embryo / Fetal Development Mouse Subcutaneous <12.5 mg/kg/day NOEL Maternal Toxicity, Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Phenytoin

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vivo Sister Chromatid Exchange Human Lymphocytes Positive
In Vivo Mitotic Spindle Assay Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Phenytoin

2 Year(s) Male Rat Oral, in feed 50 mg/kg/day NOEL Benign neoplasms, Skin
2 Year(s) Mouse Oral, in feed 25 mg/kg/day NOEL Benign tumors, Liver
2 Year(s) Female Mouse Oral, in feed 60 ppm LOAEL Liver, neoplasms
2 Year(s) Female Rat Oral, in feed 240 ppm NOAEL Not carcinogenic

Carcinogen Status: See below

Ethyl alcohol (ethanol)

IARC: Group 1 (Carcinogenic to Humans)

FD&C Yellow No. 6; (Sunset yellow)

IARC: Group 3 (Not Classifiable)

Phenytoin

IARC: Group 2B (Possibly Carcinogenic to Humans)
NTP: Reasonably Anticipated To Be A Human Carcinogen

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See aquatic toxicity data, below:

SUSPENSION

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 10 of 14
Version: 3.0

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ethyl alcohol (ethanol)

Oncorhynchus mykiss (Rainbow Trout) LC50/96h 12,900-15,300 mg/L

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L

Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Phenytoin

Hyallela azteca (Freshwater Amphipod) OPPTS LC50 96 Hours 18 mg/L

Daphnia magna (Water Flea) TAD EC50 48 Hours >39 mg/L

Pimephales promelas (Fathead Minnow) OPPTS LC50 96 Hours >23 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Phenytoin

Predicted 7.4 Log D 2.47

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 11 of 14
Version: 3.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Glycerin, USP

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5

Concentrated orange oil

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	Not Listed

Imitation banana oil

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Citric acid, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1

Carboxymethylcellulose sodium

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
 Revision date: 14-Apr-2015

Page 12 of 14
 Version: 3.0

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Ethyl alcohol (ethanol)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 4/29/11 in alcoholic beverages developmental toxicity initial date 10/1/87 in alcoholic beverages
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-578-6
FD&C Yellow No. 6; (Sunset yellow)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	220-491-7
Magnesium aluminum silicate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-478-8
Phenytoin	
CERCLA/SARA 313 Emission reporting	0.1 %
California Proposition 65	carcinogen initial date 1/1/88 developmental toxicity initial date 7/1/87
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-328-6
Polysorbate 40	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Purified water	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 13 of 14
Version: 3.0

15. REGULATORY INFORMATION

Sodium benzoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	208-534-8

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

Vanillin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-465-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Flammable liquids-Cat.2; H225 - Highly flammable liquid and vapor
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

F - Highly flammable
Carcinogenic: Category 3
Toxic to Reproduction: Category 2
Xn - Harmful

R11 - Highly flammable.
R22 - Harmful if swallowed.
R40 - Limited evidence of a carcinogenic effect
R61 - May cause harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 14-Apr-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

SAFETY DATA SHEET

Material Name: Phenytoin Oral Suspension
Revision date: 14-Apr-2015

Page 14 of 14
Version: 3.0

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet